Platform technology

Sagitta©

Developing Therapies With no Compromise ​

Sagitta© biodegradable conjugation platforms are discovered to reinforce ideal performances in terms of the therapeutic index, pharmacokinetics and manufacturability.

Sagitta©

Developing Therapies With no Compromise

Sagitta© biodegradable conjugation platforms are discovered to reinforce ideal performances in terms of the therapeutic index, pharmacokinetics and manufacturability.

EXPLORE Sagitta© Technology
Download Our Presentation
Enrich your pipeline w/ Sagitta©
contact us
clinically validated drug candidates
Check out our pipeline
HIGHER

Therapeutic Index

The dual drug loading capacity of Sagitta© yields to a synergistic therapeutic effect. Sagitta© platform is compatible with a wide range of targeting ligands or mAbs as well as a diverse choice of drugs – ensuring highest efficacy and specificity.

IMPROVED

Pharmacokinetics

Sagitta© platform significantly prolongs the circulation time compared to native API. The improvement in half-life translated across species and therefore poses predictable promise for later clinical stages.

STRAIGHT-FORWARD

Manufacturing

We manufacture our products at our own GMP certificated production facility for clinical batch lyophilized oncology drugs.

Efficacy & Specificity

Efficacy & Specificity

· Versatile structure ·
· Synergistic therapeutic effect ·
· Higher accumulation ·

Translatability

Translatability

· Pharmacokinetic parameters ·
· Predictable translation to human ·

Tolerability

Tolerability

· Reduced side effect profile ·
· Enhanced Permeability & Retention effect ·
· Selective release ·
· Biologic stimuli driven release ·

Manufacturability

Manufacturability

· Proven GMP production record ·
· High purity ·
· Scalable for clinical GMP batches ·

HIGHER

THERAPEUTIC INDEX

The dual drug loading capacity of Sagitta© yields to a synergistic therapeutic effect. Sagitta© platform is compatible with a wide range of targeting ligands or mAbs as well as a diverse choice of drugs – ensuring highest efficacy and specificity.

IMPROVED

PHARMACOKINETICS

Sagitta© platform significantly prolongs the circulation time compared to native API. The improvement in half-life translated across species and therefore poses predictable promise for later clinical stages.

 STRAIGHT-FORWARD

MANUFACTURING

We manufacture our products at our own GMP certificated production facility for clinical batch lyophilized oncology drugs.

Efficacy & Specificity

Efficacy & Specificity

· Versatile structure
· Synergistic therapeutic effect
· Higher accumulation

Tolerability

Tolerability

· Reduced side effect profile
· Enhanced Permeability & Retention effect
· Selective release
· Biologic stimuli driven release

Translatability

Translatability

· Pharmacokinetic parameters
· Predictable translation to human

Manufacturability

Manufacturability

· Proven GMP production record
· High purity
· Scalable for clinical GMP batches